CRISPR Therapeutics AG Files 8-K
Ticker: CRSP · Form: 8-K · Filed: Jun 9, 2025 · CIK: 1674416
Sentiment: neutral
Topics: corporate-governance, filing, shareholder-vote
Related Tickers: CRSP
TL;DR
CRISPR Therapeutics filed an 8-K on June 5th, likely with corporate updates. Watch for shareholder votes.
AI Summary
CRISPR Therapeutics AG filed an 8-K on June 9, 2025, reporting events that occurred on June 5, 2025. The filing indicates amendments to articles of incorporation or bylaws, submission of matters to a vote of security holders, and financial statements and exhibits. The company is incorporated in Switzerland and its fiscal year ends on December 31.
Why It Matters
This 8-K filing signals potential corporate governance changes or significant shareholder votes, which could impact the company's strategic direction and investor relations.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain any immediate negative financial or operational news.
Key Players & Entities
- CRISPR Therapeutics AG (company) — Registrant
- June 5, 2025 (date) — Date of earliest event reported
- June 9, 2025 (date) — Date of report
- Switzerland (location) — Jurisdiction of incorporation
FAQ
What specific amendments were made to CRISPR Therapeutics AG's articles of incorporation or bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the summary information.
What matters were submitted to a vote of security holders?
The filing states that matters were submitted to a vote of security holders, but the nature of these matters is not specified in the provided text.
What financial statements and exhibits are included with this 8-K filing?
The filing mentions the submission of financial statements and exhibits, but their content is not detailed in the provided summary.
When is CRISPR Therapeutics AG's fiscal year end?
CRISPR Therapeutics AG's fiscal year ends on December 31.
What is the principal executive office address for CRISPR Therapeutics AG?
The principal executive office is located at Baarerstrasse 14, 6300 Zug, Switzerland.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 9, 2025 regarding CRISPR Therapeutics AG (CRSP).